Luminex (LMNX) 10-Q 3 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 02, 2015
Entity [Abstract]
Entity Registrant Name	Luminex Corp
Entity Central Index Key	1,033,905
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		43,061,720
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 119,553	$ 91,694
Short-term Investments	12,006	0
Accounts receivable, net	26,161	28,272
Inventories, net	29,315	36,616
Deferred income taxes	5,125	12,203
Prepaids and other	9,694	8,235
Total current assets	201,854	177,020
Property and equipment, net	48,037	39,945
Intangible assets, net	53,927	56,382
Deferred income taxes	15,129	15,400
Long-term investments	4,003	15,975
Goodwill	49,619	49,619
Other	3,758	3,185
Total assets	376,327	357,526
Current liabilities:
Accounts payable	9,283	11,841
Accrued liabilities	13,005	14,118
Deferred revenue	4,373	4,407
Total current liabilities	26,661	30,366
Deferred revenue	2,119	2,297
Other	5,041	4,869
Total liabilities	33,821	37,532
Stockholders' equity:
Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 42,168,578 shares as of September 30, 2015; 41,805,962 shares at December 31, 2014	42	42
Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Additional paid-in capital	315,803	309,424
Accumulated other comprehensive loss	(1,095)	(744)
Retained earnings	27,756	11,272
Total stockholders' equity	342,506	319,994
Total liabilities and stockholders' equity	$ 376,327	$ 357,526

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS Parenthetical - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	42,168,578	41,805,962
Common stock, outstanding (in shares)	42,168,578	41,805,962
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenue	$ 60,601,000	$ 56,684,000	$ 177,259,000	$ 168,877,000
Cost of revenue	18,789,000	17,674,000	51,958,000	51,766,000
Gross profit	41,812,000	39,010,000	125,301,000	117,111,000
Operating expenses:
Research and development	10,093,000	10,327,000	31,748,000	32,719,000
Selling, general and administrative	21,236,000	21,423,000	61,740,000	61,838,000
Amortization of acquired intangible assets	777,000	964,000	2,455,000	2,949,000
Restructuring costs	0	1,300,000	0	1,653,000
Total operating expenses	32,106,000	34,014,000	95,943,000	99,159,000
Income from operations	9,706,000	4,996,000	29,358,000	17,952,000
Interest expense from long-term debt	0	0	0	(6,000)
Other income, net	13,000	(15,000)	964,000	(35,000)
Settlement of litigation	0	0	(7,300,000)	0
Income before income taxes	9,719,000	4,981,000	23,022,000	17,911,000
Income taxes	(3,317,000)	569,000	(6,538,000)	(1,670,000)
Net income	6,402,000	5,550,000	16,484,000	16,241,000
Other comprehensive loss:
Foreign currency translation adjustments	(20,000)	(410,000)	(375,000)	(814,000)
Unrealized gain (loss) on available-for-sale securities, net of tax	2,000	(15,000)	24,000	(14,000)
Other comprehensive loss	(18,000)	(425,000)	(351,000)	(828,000)
Comprehensive income	$ 6,384,000	$ 5,125,000	$ 16,133,000	$ 15,413,000
Net income per share, basic	$ 0.15	$ 0.13	$ 0.39	$ 0.39
Shares used in computing net income per share, basic	42,152	41,714	42,041	41,496
Net income per share, diluted	$ 0.15	$ 0.13	$ 0.39	$ 0.39
Shares used in computing net income per share, diluted	42,556	42,381	42,354	42,127

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Document Fiscal Year Focus			2,015
Net income	$ 6,402	$ 5,550	$ 16,484	$ 16,241
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,411	3,400	9,733	10,935
Stock-based compensation	3,099	2,622	7,768	7,052
Deferred income tax (benefit) expense	176	(3,568)	6,207	(1,048)
Excess income tax (benefit) expense from employee stock-based awards	14	(1,315)	1,005	(1,315)
(Gain) loss on sale or disposal of assets	(62)	48	(743)	231
Non-cash restructuring charges	0	1,192	0	2,388
Other	(25)	(28)	(128)	(360)
Changes in operating assets and liabilities:
Accounts receivable, net	(3,985)	203	2,101	3,742
Inventories, net	3,364	(1,943)	7,414	(3,465)
Other assets	764	(829)	(1,629)	(792)
Accounts payable	1,238	1,227	(2,536)	(878)
Accrued liabilities	(3,466)	4,922	(3,078)	407
Deferred revenue	(36)	46	(212)	53
Net cash provided by operating activities	10,894	11,527	42,386	33,191
Cash flows from investing activities:
Purchases of available-for-sale securities	0	(8,000)	0	(10,996)
Maturities of available-for-sale securities	0	2,996	0	7,509
Purchase of property and equipment	(2,731)	(5,540)	(15,299)	(11,795)
Proceeds from sale of assets	0	5	893	44
Acquired technology rights	(650)	0	(852)	(64)
Net cash used in investing activities	(3,381)	(10,539)	(15,258)	(15,302)
Cash flows from financing activities:
Payments on debt	0	0	0	1,621
Proceeds from employee stock plans and issuance of common stock	977	327	1,690	3,807
Excess income tax (benefit) expense from employee stock-based awards	(14)	1,315	(1,005)	1,315
Net cash provided by financing activities	963	1,642	685	3,501
Effect of foreign currency exchange rate on cash	13	(217)	46	(191)
Change in cash and cash equivalents	8,489	2,413	27,859	21,199
Cash and cash equivalents, beginning of period	111,064	86,710	91,694	67,924
Cash and cash equivalents, end of period	$ 119,553	$ 89,123	$ 119,553	$ 89,123

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1 — BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the “Company” or “Luminex”) in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 . These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 (the " 2014 10-K"). The Company has reclassified certain 2014 amounts in the accompanying condensed consolidated balance sheet to conform to the 2015 presentation. These reclassifications include $0.8 million from Accounts receivable, net to Prepaids and other. This reclassification was not material to the Company's consolidated financial statements.

RESTRUCTURING RESTRUCTURING

RESTRUCTURING RESTRUCTURING	9 Months Ended
	Sep. 30, 2015
RESTRUCTURING [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	NOTE 2 — RESTRUCTURING In August 2013, the Company announced a restructuring plan focused on its Newborn Screening Group and its Brisbane, Australia office where automated punching systems were designed and manufactured. The Company halted development of the newborn screening assay in 2013 and the manufacturing facility in Brisbane, Australia was closed in the third quarter of 2014. The Company reviewed the requirements for held-for-sale and discontinued operations presentation and determined the manufacturing facility in Brisbane, Australia did not meet the definition of a discontinued operation. The Company recorded pre-tax restructuring charges primarily consisting of the non-cash impairment of inventory, intangible assets and property and equipment, together with employee separation costs, which primarily included severance pay and other separation costs such as outplacement services and benefits. The Company recorded non-cash impairment charges of $2.8 million in 2014, including a write-down of goodwill of $1.2 million resulting from the disposal of the manufacturing facility in Brisbane, Australia. See Note 6 — Goodwill and Other Intangible Assets. In addition, the Company measured and accrued the facilities exit costs, primarily consisting of cease-use losses recorded upon vacating the facilities, at fair value upon the Company's exit in the third quarter of 2014. As the final restructuring costs were paid in the fourth quarter of 2014, there is no remaining balance of accrued restructuring costs as of September 30, 2015 or December 31, 2014 . 2013 Restructuring Plan Year Ended December 31, 2014 Non-cash impairment charges: Inventory $ 1,183 Property and equipment 494 Goodwill 1,159 Employee separation costs 154 Facility exit costs 69 Other 41 Total charges $ 3,100 Recorded to cost of revenue 1,218 Recorded to restructuring costs $ 1,882

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2015
Investments [Abstract]
INVESTMENTS	NOTE 3 — INVESTMENTS Marketable Securities The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates the fair value of these investments. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity. As of September 30, 2015 and December 31, 2014 , all of the Company’s marketable securities were classified as available-for-sale. Marketable securities are recorded as either short-term or long-term on the balance sheet based on the contractual maturity date. The fair value of all securities is determined by quoted market prices, market interest rates inputs, or other than quoted prices that are observable either directly or indirectly (as of the end of the reporting period). Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings. Available-for-sale securities consisted of the following as of September 30, 2015 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Cash equivalents $ 3,610 $ — $ — $ 3,610 Government sponsored debt securities 8,003 6 — 8,009 Non-government sponsored debt securities 4,000 — (3 ) 3,997 Total current securities 15,613 6 (3 ) 15,616 Noncurrent: Government sponsored debt securities 1,997 3 — 2,000 Non-government sponsored debt securities 2,001 2 — 2,003 Total noncurrent securities 3,998 5 — 4,003 Total available-for-sale securities $ 19,611 $ 11 $ (3 ) $ 19,619 Available-for-sale securities consisted of the following as of December 31, 2014 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Cash equivalents $ 3,569 $ — $ — $ 3,569 Total current securities 3,569 — — 3,569 Noncurrent: Government sponsored debt securities 10,000 — (11 ) 9,989 Non-government sponsored debt securities 6,002 — (16 ) 5,986 Total noncurrent securities 16,002 — (27 ) 15,975 Total available-for-sale securities $ 19,571 $ — $ (27 ) $ 19,544 There were no proceeds from the sales of available-for-sale securities during the three and nine months ended September 30, 2015 or 2014 . Realized gains and losses on sales of investments are determined using the specific identification method. Realized gains and losses are included in Other income, net in the Consolidated Statements of Comprehensive Income. All of the Company's available-for-sale securities with gross unrealized holding losses as of September 30, 2015 and December 31, 2014 had been in a loss position for less than 12 months. The estimated fair value of available-for-sale debt securities as of September 30, 2015 and December 31, 2014 , by contractual maturity, was as follows (in thousands): Estimated Fair Value September 30, 2015 December 31, 2014 Due in one year or less $ 12,006 $ — Due after one year through two years 4,003 15,975 $ 16,009 $ 15,975 Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Non-Marketable Securities and Other-Than-Temporary Impairment The Company owns a minority interest in a private company based in the U.S. through its investment of $1.0 million in the third quarter of 2012. This minority interest is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee since the Company owns less than 20% of the voting equity in the investee and the investee is not publicly traded. The Company's other minority interest in a private company was acquired by a third party in July 2013. The Company realized a gain of $5.4 million on the sale of this minority interest investment in the third quarter of 2013 and an additional gain of $0.9 million in the first quarter of 2015 related to the settlement of escrowed funds. The Company regularly evaluates the carrying value of its cost-method investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee's ability to remain in business, such as the investee's liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is judged to be other-than-temporary, the Company will record an other-than-temporary impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. As the inputs utilized for the Company's periodic impairment assessment are not based on observable market data, this cost-method investment is classified within Level 3 of the fair value hierarchy. To determine the fair value of this investment, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost-method investment's fair value is not estimated as there are no identified events or changes in the circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical.

INVENTORY, NET

INVENTORY, NET	9 Months Ended
	Sep. 30, 2015
Inventory, Net [Abstract]
INVENTORIES, NET	NOTE 4 — INVENTORIES, NET Inventories are stated at the lower of cost or market, with cost determined according to the standard cost method, which approximates the first-in, first-out method. The Company routinely assesses its on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. Inventories consisted of the following (in thousands): September 30, 2015 December 31, 2014 Parts and supplies $ 14,679 $ 19,354 Work-in-progress 7,311 8,687 Finished goods 7,325 8,575 $ 29,315 $ 36,616

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 5 — FAIR VALUE MEASUREMENT The Fair Value Measurements and Disclosures Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The ASC describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2, or Level 3 measurements for the three month period ended September 30, 2015 . The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014 (in thousands): Fair Value Measurements as of September 30, 2015 Using Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 3,610 $ — $ — $ 3,610 Government sponsored debt securities — 10,009 — 10,009 Non-government sponsored debt securities — 6,000 — 6,000 Fair Value Measurements as of December 31, 2014 Using Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 3,569 $ — $ — $ 3,569 Government sponsored debt securities — 9,989 — $ 9,989 Non-government sponsored debt securities — 5,986 — $ 5,986

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	NOTE 6 — GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise. The Company's goodwill is not expected to be deductible for tax purposes. The current in-process research and development project is related to the Company's acquisition of GenturaDx, the foundation of our ARIES ® System, in 2012. The Company received U.S. Food and Drug Administration ("FDA") clearance for the Company's ARIES ® System and ARIES ® HSV 1&2 Assay in October 2015. Therefore, we expect this in-process research and development project will be classified as finite-lived technology beginning in October 2015 and begin amortizing. The additional estimated amortization expense related to this project for 2016 through 2019 is estimated to be approximately $3.6 million per year, and approximately $25.6 million thereafter. In connection with the closure of the manufacturing facility in Brisbane, Australia in the third quarter of 2014, the Company recorded a write-down of goodwill of $1.2 million . The amount of goodwill the Company included in the carrying amount of the disposed manufacturing business in Brisbane, Australia was based upon the relative fair value of that facility compared to the portion of the reporting unit that was retained. The changes in the carrying amount of the Company’s goodwill during the period are as follows (in thousands): September 30, 2015 December 31, 2014 Balance at beginning of year $ 49,619 $ 50,738 Allocation in disposal of Brisbane, Australia business (See Note 2) — (1,159 ) Foreign currency translation adjustments — 40 Balance at end of period $ 49,619 $ 49,619 The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives): Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2014 Balance as of December 31, 2013 $ 29,676 $ 7,952 $ 1,880 $ 40,100 $ 79,608 Foreign currency translation adjustments 28 6 10 — 44 Balance as of December 31, 2014 29,704 7,958 1,890 40,100 79,652 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2013 (16,272 ) (2,326 ) (715 ) — (19,313 ) Amortization expense (3,025 ) (753 ) (135 ) — (3,913 ) Foreign currency translation adjustments (28 ) (6 ) (10 ) — (44 ) Accumulated amortization balance as of December 31, 2014 (19,325 ) (3,085 ) (860 ) — (23,270 ) Net balance as of December 31, 2014 $ 10,379 $ 4,873 $ 1,030 $ 40,100 $ 56,382 Weighted average life (in years) 10 11 11 2015 Balance as of December 31, 2014 $ 29,704 $ 7,958 $ 1,890 $ 40,100 $ 79,652 Removal of fully amortized assets (702 ) (161 ) (238 ) — (1,101 ) Balance as of September 30, 2015 29,002 7,797 1,652 40,100 78,551 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2014 (19,325 ) (3,085 ) (860 ) — (23,270 ) Amortization expense (1,798 ) (557 ) (100 ) — (2,455 ) Removal of fully amortized assets 702 161 238 — 1,101 Accumulated amortization balance as of September 30, 2015 (20,421 ) (3,481 ) (722 ) — (24,624 ) Net balance as of September 30, 2015 $ 8,581 $ 4,316 $ 930 $ 40,100 $ 53,927 Weighted average life (in years) 10 11 11 The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands): 2015 (three months) $ 777 2016 3,100 2017 2,144 2018 1,954 2019 1,954 Thereafter 3,898 13,827 IP R&D 40,100 $ 53,927

OTHER COMPREHENSIVE (LOSS) INCO

OTHER COMPREHENSIVE (LOSS) INCOME	9 Months Ended
	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Comprehensive Income (Loss) Note	NOTE 7 — OTHER COMPREHENSIVE INCOME (LOSS) Other comprehensive income (loss) represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive income (loss) for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments. The following table presents the changes in each component of accumulated other comprehensive income (loss), net of tax (in thousands): Foreign Currency Items Available-for-Sale Investments Accumulated Other Comprehensive Loss Items Balance as of December 31, 2014 $ (727 ) $ (17 ) $ (744 ) Other comprehensive loss (income) before reclassifications (375 ) 24 (351 ) Amounts reclassified from accumulated other comprehensive income (loss) — — — Net current-period other comprehensive (loss) income (375 ) 24 (351 ) Balance as of September 30, 2015 $ (1,102 ) $ 7 $ (1,095 ) The following table presents the tax (expense) benefit allocated to each component of other comprehensive income (loss) (in thousands): Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Before Tax Tax Benefit Net of Tax Before Tax Tax Benefit Net of Tax Foreign currency translation adjustments $ (19 ) $ — $ (19 ) $ (375 ) $ — $ (375 ) Unrealized losses on available-for-sale investments 1 — 1 36 (12 ) 24 Other comprehensive income (loss) $ (18 ) $ — $ (18 ) $ (339 ) $ (12 ) $ (351 )

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE 8 — EARNINGS PER SHARE A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Numerator: Net income $ 6,402 $ 5,550 $ 16,484 $ 16,241 Denominator: Denominator for basic net income per share - weighted average common stock outstanding 42,152 41,714 42,041 41,496 Effect of dilutive securities: stock options and awards 404 667 313 631 Denominator for diluted net income per share - weighted average shares outstanding - diluted 42,556 42,381 42,354 42,127 Basic net income per share $ 0.15 $ 0.13 $ 0.39 $ 0.39 Diluted net income per share $ 0.15 $ 0.13 $ 0.39 $ 0.39 Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Stock options to acquire approximately 0.6 million and 0.2 million shares for the three months ended September 30, 2015 and 2014 , respectively, and 0.6 million and 0.2 million shares for the nine months ended September 30, 2015 and 2014 , respectively, were excluded from the computations of diluted EPS because the effect of including those stock options would have been anti-dilutive.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	NOTE 9 — STOCK-BASED COMPENSATION The Company’s stock option activity for the nine months ended September 30, 2015 was as follows: Stock Options (shares in thousands) Shares Weighted Average Exercise Price Outstanding as of December 31, 2014 825 $ 18.84 Granted 962 15.94 Exercised (55 ) 13.84 Cancelled or expired (21 ) 16.68 Outstanding as of September 30, 2015 1,711 $ 17.40 The Company had $7.8 million of total unrecognized compensation costs related to stock options as of September 30, 2015 that are expected to be recognized over a weighted average period of 3.28 years . The Company’s restricted share activity for the nine months ended September 30, 2015 was as follows: Restricted Stock Awards (shares in thousands) Shares Weighted Average Grant Price Non-vested as of December 31, 2014 1,098 $ 19.63 Granted 276 15.95 Vested (322 ) 19.17 Cancelled or expired (152 ) 19.29 Non-vested as of September 30, 2015 900 $ 18.73 Restricted Stock Units (in thousands) Shares Non-vested as of December 31, 2014 658 Granted 122 Vested (53 ) Cancelled or expired (195 ) Non-vested as of September 30, 2015 532 As of September 30, 2015 , there was $17.1 million and $3.9 million of total unrecognized compensation costs related to RSAs and RSUs, respectively. That cost is expected to be recognized over a weighted average period of 2.63 years for the RSAs and 2.12 years for the RSUs. The Company issues a small number of cash settled restricted stock units pursuant to the Company's equity incentive plan in certain foreign countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company. The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of comprehensive income (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of revenue $ 238 $ 233 $ 742 $ 743 Research and development 725 726 1,705 1,862 Selling, general and administrative 2,136 1,663 5,321 4,447 Stock-based compensation costs reflected in net income $ 3,099 $ 2,622 $ 7,768 $ 7,052

ACCRUED LIABILITIES

ACCRUED LIABILITIES	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities, Current [Abstract]
ACCRUED WARRANTY COSTS	NOTE 10 — ACCRUED LIABILITIES Accrued liabilities consisted of the following (in thousands): September 30, 2015 December 31, 2014 Compensation and employee benefits $ 9,335 $ 9,960 Income and other taxes 846 870 Warranty costs 459 488 Other 2,365 2,800 $ 13,005 $ 14,118 Sales of certain of the Company's systems are subject to a warranty. System warranties typically extend for a period of 12 months from the date of installation not to exceed 24 months from the date of shipment. The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data. The actual warranty expense could differ from the estimates made by the Company based on product performance. Warranty expenses are evaluated and adjusted periodically. The following table summarizes the changes in the warranty accrual (in thousands): Accrued warranty costs as of December 31, 2014 $ 488 Warranty adjustments/settlements (465 ) Accrual for warranty costs 436 Accrued warranty costs as of September 30, 2015 $ 459

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 — INCOME TAXES At the end of each interim reporting period, an estimate is made of the effective tax rate expected to be applicable for the full year. The estimated full year’s effective tax rate is used to determine the income tax rate for each applicable interim reporting period. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. The effective tax rate for the nine months ended September 30, 2015 was 28.40% , including amounts recorded for discrete events. This differs from the statutory rate of 35% primarily because of the worldwide mix of consolidated earnings and losses before taxes and an assessment regarding the realizability of the Company’s deferred tax assets. The Company’s tax expense reflects the full federal, various state, and foreign blended statutory rates. The Company is utilizing its net operating losses and tax credits in the U.S., Canada and the Netherlands and currently expects a full year effective tax rate of less than 30% . Therefore, cash taxes to be paid are expected to continue to be less than 50% of book tax expense. The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, Australia, Canada, China, Hong Kong, Japan, the Netherlands, and various states. Due to net operating losses, the U.S., Canadian and Australian tax returns dating back to 2010 can still be reviewed by the taxing authorities. No other material changes to this liability are expected within the next 12 months. For the nine months ended September 30, 2015 , there were no material changes to the total amount of unrecognized tax benefits. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 - COMMITMENTS AND CONTINGENCIES On August 30, 2012, Abbott Laboratories, Inc. ("Abbott") was named as a defendant in a complaint filed by ENZO Life Sciences, Inc. ("ENZO") in U.S. District Court in Delaware for alleged infringement of U.S. Patent 7,064,197 as a result of Abbott's distribution of Luminex's xTAG Respiratory Viral Panel. Luminex and Abbott entered into an agreement requiring Luminex to defend and indemnify Abbott for any alleged patent infringement resulting from its distribution of Luminex's xTAG Respiratory Viral Panel. The complaint sought unspecified monetary damages and injunctive relief. Abbott filed an answer to the complaint on October 15, 2012. On November 30, 2012, Luminex intervened in the lawsuit. On January 2, 2013, ENZO filed additional claims against Luminex, alleging infringement of U.S. Patent 7,064,197 resulting from Luminex's sale of its xTAG, FlexScript LDA, SelecTAG, and xMAP Salmonella Serotyping Assay products and alleging infringement of U.S. Patent 8,097,405 resulting from Luminex's sale of MultiCode products. Luminex filed an answer to ENZO's additional claims on January 28, 2013. On October 2, 2013, ENZO filed additional claims against Luminex, alleging infringement of U.S. Patent 6,992,180 resulting from Luminex’s sale of MultiCode products. Luminex filed an answer to ENZO’s additional claims on October 21, 2013. Effective July 2, 2015, Luminex agreed to pay ENZO $7.1 million to settle the litigation. This settlement resulted in the entry of orders dismissing (i) with prejudice all claims, counterclaims and causes of action asserted by ENZO against Luminex, (ii) without prejudice all claims, counterclaims and causes of action asserted by Luminex against ENZO, (iii) with prejudice all claims, counterclaims and causes of action solely under U.S. Patent 7,064,197 asserted in the litigation by ENZO against Abbott and (iv) without prejudice all claims, counterclaims and causes of action relating solely to U.S. Patent 7,064,197 asserted by Abbott against ENZO; and resulted in the grant to the Company and its affiliates of a fully paid, non-exclusive, worldwide license under the patents asserted in the complaint. In addition, the Company and ENZO released each other from certain claims related to the above-referenced patents, including the claims and counterclaims asserted in the complaint. ENZO further released Abbott from certain claims, including those asserted in the complaint, related solely to U.S. Patent 7,064,197. The settlement was entered into solely by way of compromise and does not constitute an admission or concession by Luminex of any liability or wrongdoing. Because Luminex (i) has never paid any royalties to ENZO in the past, (ii) will not be required to pay any future or ongoing royalties to ENZO as a result of the settlement, (iii) has never recorded any revenue or expense related to ENZO in operating revenue or in operating expenses in the past, outside of legal fees, and (iv) believes that it does not infringe on any valid and enforceable claim with respect to the asserted patents, Luminex determined that this settlement of litigation expense was outside of operations. Luminex accordingly recorded the settlement as a separate, non-operating line item in the second quarter of 2015. Luminex made the $7.1 million payment to ENZO in July 2015. On November 1, 2013, Irori Technologies, Inc. ("Irori") filed a complaint against Luminex in U.S. District Court in the Southern District of California alleging infringement of its U.S. Patents 6,372,428, 6,416,714, and 6,352,854 resulting from Luminex’s sale of its xMAP and xTAG based products. Luminex filed a motion to dismiss on January 9, 2014. Irori filed its response to our motion to dismiss on February 7, 2014. The court granted the motion to dismiss without prejudice on February 25, 2014. On March 18, 2014, Irori filed an amended complaint, again alleging infringement of U.S. Patents 6,372,428, 6,416,714, and 6,352,854 resulting from Luminex’s sale of its xMAP and xTAG based products. The complaint seeks unspecified monetary damages and injunctive relief. Luminex filed an answer to Irori’s amended complaint on April 2, 2014. On June 10, 2014, Luminex filed with the USPTO’s Patent Trial and Appeal Board a total of five petitions for inter partes review ("IPR") seeking to invalidate the claims of the three patents involved in the litigation. On June 17, 2014, Luminex filed a motion to stay proceedings in the district court pending the USPTO’s resolution of the IPR of Irori’s patents. Irori filed its opposition to the motion to stay on July 7, 2014, and Luminex filed a reply on July 14, 2014. On July 16, 2014, the court granted Luminex’s motion to stay the case until the earlier of i) a determination by the United States Patent and Trademark Office that reexamination proceedings will not take place or ii) the conclusion of reexamination proceedings and appeals. On December 11, 2014, the USPTO's Patent Trial and Appeal Board instituted review on all five IPR petitions that Luminex filed. On March 5, 2015 Luminex and Irori reached a settlement. The settlement amount was not material. On March 19, 2015 the district court dismissed Irori's lawsuit with prejudice. On March 26, 2015, the IPR petitions were terminated. When and if it appears probable in management's judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements. If only a range of estimated losses can be estimated, we record an amount within the range that, in management's judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 13 — RECENT ACCOUNTING PRONOUNCEMENTS In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

SUBSEQUENT EVENTS (Notes)

SUBSEQUENT EVENTS (Notes)	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 14 — SUBSEQUENT EVENTS In October 2015, Luminex settled a lawsuit that we filed in 2013 against a third party alleging breach of contract and patent infringement for a $2.0 million lump sum payment. We received the $2.0 million payment in October, 2015 and are recording the settlement as non-operating other revenue in the fourth quarter of 2015.

RESTRUCTURING RESTRUCTURING (Ta

RESTRUCTURING RESTRUCTURING (Tables)	9 Months Ended
	Sep. 30, 2015
RESTRUCTURING [Abstract]
Restructuring and Related Costs [Table Text Block]	2013 Restructuring Plan Year Ended December 31, 2014 Non-cash impairment charges: Inventory $ 1,183 Property and equipment 494 Goodwill 1,159 Employee separation costs 154 Facility exit costs 69 Other 41 Total charges $ 3,100 Recorded to cost of revenue 1,218 Recorded to restructuring costs $ 1,882

INVESTMENTS (Tables)

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2015
Investments [Abstract]
Components of available-for-sale securities	Available-for-sale securities consisted of the following as of September 30, 2015 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Cash equivalents $ 3,610 $ — $ — $ 3,610 Government sponsored debt securities 8,003 6 — 8,009 Non-government sponsored debt securities 4,000 — (3 ) 3,997 Total current securities 15,613 6 (3 ) 15,616 Noncurrent: Government sponsored debt securities 1,997 3 — 2,000 Non-government sponsored debt securities 2,001 2 — 2,003 Total noncurrent securities 3,998 5 — 4,003 Total available-for-sale securities $ 19,611 $ 11 $ (3 ) $ 19,619 Available-for-sale securities consisted of the following as of December 31, 2014 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Cash equivalents $ 3,569 $ — $ — $ 3,569 Total current securities 3,569 — — 3,569 Noncurrent: Government sponsored debt securities 10,000 — (11 ) 9,989 Non-government sponsored debt securities 6,002 — (16 ) 5,986 Total noncurrent securities 16,002 — (27 ) 15,975 Total available-for-sale securities $ 19,571 $ — $ (27 ) $ 19,544
Estimated fair value of available-for-sale debt securities, by contractual maturity	The estimated fair value of available-for-sale debt securities as of September 30, 2015 and December 31, 2014 , by contractual maturity, was as follows (in thousands): Estimated Fair Value September 30, 2015 December 31, 2014 Due in one year or less $ 12,006 $ — Due after one year through two years 4,003 15,975 $ 16,009 $ 15,975

INVENTORY, NET (Tables)

INVENTORY, NET (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory, Net [Abstract]
Schedule of Inventory, Current	Inventories consisted of the following (in thousands): September 30, 2015 December 31, 2014 Parts and supplies $ 14,679 $ 19,354 Work-in-progress 7,311 8,687 Finished goods 7,325 8,575 $ 29,315 $ 36,616

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair value, financial assets (cash equivalents and investments) measured on a recurring basis	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014 (in thousands): Fair Value Measurements as of September 30, 2015 Using Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 3,610 $ — $ — $ 3,610 Government sponsored debt securities — 10,009 — 10,009 Non-government sponsored debt securities — 6,000 — 6,000 Fair Value Measurements as of December 31, 2014 Using Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 3,569 $ — $ — $ 3,569 Government sponsored debt securities — 9,989 — $ 9,989 Non-government sponsored debt securities — 5,986 — $ 5,986

GOODWILL AND OTHER INTANGIBLE24

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the carrying amount of goodwill	The changes in the carrying amount of the Company’s goodwill during the period are as follows (in thousands): September 30, 2015 December 31, 2014 Balance at beginning of year $ 49,619 $ 50,738 Allocation in disposal of Brisbane, Australia business (See Note 2) — (1,159 ) Foreign currency translation adjustments — 40 Balance at end of period $ 49,619 $ 49,619
Schedule of intangible assets	The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives): Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2014 Balance as of December 31, 2013 $ 29,676 $ 7,952 $ 1,880 $ 40,100 $ 79,608 Foreign currency translation adjustments 28 6 10 — 44 Balance as of December 31, 2014 29,704 7,958 1,890 40,100 79,652 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2013 (16,272 ) (2,326 ) (715 ) — (19,313 ) Amortization expense (3,025 ) (753 ) (135 ) — (3,913 ) Foreign currency translation adjustments (28 ) (6 ) (10 ) — (44 ) Accumulated amortization balance as of December 31, 2014 (19,325 ) (3,085 ) (860 ) — (23,270 ) Net balance as of December 31, 2014 $ 10,379 $ 4,873 $ 1,030 $ 40,100 $ 56,382 Weighted average life (in years) 10 11 11 2015 Balance as of December 31, 2014 $ 29,704 $ 7,958 $ 1,890 $ 40,100 $ 79,652 Removal of fully amortized assets (702 ) (161 ) (238 ) — (1,101 ) Balance as of September 30, 2015 29,002 7,797 1,652 40,100 78,551 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2014 (19,325 ) (3,085 ) (860 ) — (23,270 ) Amortization expense (1,798 ) (557 ) (100 ) — (2,455 ) Removal of fully amortized assets 702 161 238 — 1,101 Accumulated amortization balance as of September 30, 2015 (20,421 ) (3,481 ) (722 ) — (24,624 ) Net balance as of September 30, 2015 $ 8,581 $ 4,316 $ 930 $ 40,100 $ 53,927 Weighted average life (in years) 10 11 11
Estimated aggregate amortization expense for the next five years and thereafter	The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands): 2015 (three months) $ 777 2016 3,100 2017 2,144 2018 1,954 2019 1,954 Thereafter 3,898 13,827 IP R&D 40,100 $ 53,927

OTHER COMPREHENSIVE (LOSS) IN25

OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	9 Months Ended
	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table presents the changes in each component of accumulated other comprehensive income (loss), net of tax (in thousands): Foreign Currency Items Available-for-Sale Investments Accumulated Other Comprehensive Loss Items Balance as of December 31, 2014 $ (727 ) $ (17 ) $ (744 ) Other comprehensive loss (income) before reclassifications (375 ) 24 (351 ) Amounts reclassified from accumulated other comprehensive income (loss) — — — Net current-period other comprehensive (loss) income (375 ) 24 (351 ) Balance as of September 30, 2015 $ (1,102 ) $ 7 $ (1,095 )
Schedule of Comprehensive Income (Loss)	The following table presents the tax (expense) benefit allocated to each component of other comprehensive income (loss) (in thousands): Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Before Tax Tax Benefit Net of Tax Before Tax Tax Benefit Net of Tax Foreign currency translation adjustments $ (19 ) $ — $ (19 ) $ (375 ) $ — $ (375 ) Unrealized losses on available-for-sale investments 1 — 1 36 (12 ) 24 Other comprehensive income (loss) $ (18 ) $ — $ (18 ) $ (339 ) $ (12 ) $ (351 )

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Numerator: Net income $ 6,402 $ 5,550 $ 16,484 $ 16,241 Denominator: Denominator for basic net income per share - weighted average common stock outstanding 42,152 41,714 42,041 41,496 Effect of dilutive securities: stock options and awards 404 667 313 631 Denominator for diluted net income per share - weighted average shares outstanding - diluted 42,556 42,381 42,354 42,127 Basic net income per share $ 0.15 $ 0.13 $ 0.39 $ 0.39 Diluted net income per share $ 0.15 $ 0.13 $ 0.39 $ 0.39

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock options activity	The Company’s stock option activity for the nine months ended September 30, 2015 was as follows: Stock Options (shares in thousands) Shares Weighted Average Exercise Price Outstanding as of December 31, 2014 825 $ 18.84 Granted 962 15.94 Exercised (55 ) 13.84 Cancelled or expired (21 ) 16.68 Outstanding as of September 30, 2015 1,711 $ 17.40
Restricted shares activity	The Company’s restricted share activity for the nine months ended September 30, 2015 was as follows: Restricted Stock Awards (shares in thousands) Shares Weighted Average Grant Price Non-vested as of December 31, 2014 1,098 $ 19.63 Granted 276 15.95 Vested (322 ) 19.17 Cancelled or expired (152 ) 19.29 Non-vested as of September 30, 2015 900 $ 18.73 Restricted Stock Units (in thousands) Shares Non-vested as of December 31, 2014 658 Granted 122 Vested (53 ) Cancelled or expired (195 ) Non-vested as of September 30, 2015 532
Stock-based compensation costs recognized in consolidated statements of income	The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of comprehensive income (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of revenue $ 238 $ 233 $ 742 $ 743 Research and development 725 726 1,705 1,862 Selling, general and administrative 2,136 1,663 5,321 4,447 Stock-based compensation costs reflected in net income $ 3,099 $ 2,622 $ 7,768 $ 7,052

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consisted of the following (in thousands): September 30, 2015 December 31, 2014 Compensation and employee benefits $ 9,335 $ 9,960 Income and other taxes 846 870 Warranty costs 459 488 Other 2,365 2,800 $ 13,005 $ 14,118
Changes in warranty accrual	The following table summarizes the changes in the warranty accrual (in thousands): Accrued warranty costs as of December 31, 2014 $ 488 Warranty adjustments/settlements (465 ) Accrual for warranty costs 436 Accrued warranty costs as of September 30, 2015 $ 459

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) $ in Millions	12 Months Ended
	Dec. 31, 2014USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prior Period Reclassification Adjustment	$ 0.8

RESTRUCTURING (Details)

RESTRUCTURING (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges		$ 1,159	$ 2,800
Employee Separation Costs			154
Facility Exit Costs			69
Other Restructuring Costs			41
Total Restructuring Charges			3,100
Restructuring Charges Included In Cost Of Revenue			1,218
Restructuring Charges And Associated Cost			1,882
Inventories [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges			1,183
Property, Plant and Equipment [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges			494
Goodwill [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges	$ 0		$ (1,159)

INVESTMENTS (Details)

INVESTMENTS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2014
Components of Available-for-sale Securities [Line Items]
Amortized Cost	$ 19,611			$ 19,571
Gains in Accumulated Other Comprehensive Gain	11			0
Losses in Accumulated Other Comprehensive Gain	(3)			(27)
Non-government sponsored debt securities fair value disclosure	6,000			5,986
Government sponsored debt securities fair value disclosure	10,009			9,989
Estimated Fair Value	19,619			19,544
Available-for-sale Securities [Abstract]
Proceeds from sales of available-for-sale-securities	0		$ 0
Available-for-sale securities, debt maturities [Abstract]
Due in one year or less	12,006			0
Due after one year through two years	4,003			15,975
Total estimated fair value of available-for-sale debt securities	$ 16,009			15,975
Ownership percentage in cost method investment	20.00%
Money Market Funds [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	$ 3,610			3,569
Gains in Accumulated Other Comprehensive Gain	0			0
Losses in Accumulated Other Comprehensive Gain	0			0
Estimated Fair Value	3,610			3,569
Current government-sponsored debt securities [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	8,003
Gains in Accumulated Other Comprehensive Gain	6
Losses in Accumulated Other Comprehensive Gain	0
Estimated Fair Value	8,009
Current Non-Government Sponsored Debt Securities [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	4,000
Gains in Accumulated Other Comprehensive Gain	0
Losses in Accumulated Other Comprehensive Gain	(3)
Estimated Fair Value	3,997
Total Current Available-for-sale Securities [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	15,613			3,569
Gains in Accumulated Other Comprehensive Gain	6			0
Losses in Accumulated Other Comprehensive Gain	(3)			0
Estimated Fair Value	15,616			3,569
Non-current government sponsored debt securities
Components of Available-for-sale Securities [Line Items]
Amortized Cost	1,997			10,000
Gains in Accumulated Other Comprehensive Gain	3			0
Losses in Accumulated Other Comprehensive Gain	0			(11)
Government sponsored debt securities fair value disclosure	2,000
Estimated Fair Value				9,989
Non-Current Non-Government Sponsored Debt Securities [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	2,001			6,002
Gains in Accumulated Other Comprehensive Gain	2			0
Losses in Accumulated Other Comprehensive Gain	0			(16)
Non-government sponsored debt securities fair value disclosure	2,003
Estimated Fair Value				5,986
Total Non-Current Available-for-sale Securities [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	3,998			16,002
Gains in Accumulated Other Comprehensive Gain	5			0
Losses in Accumulated Other Comprehensive Gain	0			(27)
Estimated Fair Value	4,003			$ 15,975
Investment in Private Company 1 [Member]
Available-for-sale securities, debt maturities [Abstract]
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	900	$ 5,400
Investment in Private Company 2 [Member]
Available-for-sale securities, debt maturities [Abstract]
Amount of investments in a private company	$ 1,000

INVENTORY, NET (Details)

INVENTORY, NET (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Parts and supplies	$ 14,679	$ 19,354
Work-in-progress	7,311	8,687
Finished goods	7,325	8,575
Inventory, net	$ 29,315	$ 36,616

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Amounts included in asset accounts [Abstract]
Money Market funds	$ 3,610	$ 3,569
Government sponsored debt securities fair value disclosure	10,009	9,989
Non-government sponsored debt securities fair value disclosure	6,000	5,986
Fair Value, Inputs, Level 1 [Member]
Amounts included in asset accounts [Abstract]
Money Market funds	3,610	3,569
Government sponsored debt securities fair value disclosure	0	0
Non-government sponsored debt securities fair value disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Amounts included in asset accounts [Abstract]
Money Market funds	0	0
Government sponsored debt securities fair value disclosure	10,009	9,989
Non-government sponsored debt securities fair value disclosure	6,000	5,986
Fair Value, Inputs, Level 3 [Member]
Amounts included in asset accounts [Abstract]
Money Market funds	0	0
Government sponsored debt securities fair value disclosure	0	0
Non-government sponsored debt securities fair value disclosure	0	$ 0
Non-Current Non-Government Sponsored Debt Securities [Member]
Amounts included in asset accounts [Abstract]
Non-government sponsored debt securities fair value disclosure	$ 2,003

GOODWILL AND OTHER INTANGIBLE34

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Intangible Assets [Line Items]
Asset Impairment Charges		$ 1,159			$ 2,800
Goodwill [Roll Forward]
Balance at beginning of year			$ 49,619	$ 50,738	50,738
Foreign currency translation adjustments			0		40
Balance at end of period	$ 49,619		49,619		49,619
Finite and Indefinite-lived Intangible Assets [Roll Forward]
Balance, beginning			79,652	79,608	79,608
Removal of fully amortized assets			(1,101)
Foreign currency translation adjustments					44
Balance, ending	78,551		78,551		79,652
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance			(23,270)	(19,313)	(19,313)
Amortization expense	(777)	$ (964)	(2,455)	(2,949)	(3,913)
Removal of amortization of fully amortized assets			1,101
Foreign currency translation adjustments					(44)
Accumulated amortization, ending balance	(24,624)		(24,624)		(23,270)
Net balance	53,927		53,927		56,382
Estimated aggregate amortization expense for the next five years and thereafter [Abstract]
2015 (three months)	777		777
2,016	3,100		3,100
2,017	2,144		2,144
2,018	1,954		1,954
2,019	1,954		1,954
Thereafter	3,898		3,898
Total	13,827		13,827
IP R&D	40,100		40,100
Total	53,927		53,927
Intangible Assets Amortization Expense, In-process Research and Development, Years Two-Five	3,600		3,600
Intangible Assets Amortization Expense In process Research and Development After Year Five	25,600		25,600
In-process Research and Development [Member]
Finite and Indefinite-lived Intangible Assets [Roll Forward]
Balance, beginning			40,100	40,100	40,100
Removal of fully amortized assets			0
Foreign currency translation adjustments					0
Balance, ending	40,100		40,100		40,100
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance			0	0	0
Amortization expense			0		0
Removal of amortization of fully amortized assets			0
Foreign currency translation adjustments					0
Accumulated amortization, ending balance	0		0		0
Net balance	40,100		40,100		40,100
Technology, Trade Secrets, and Know-how [Member]
Finite and Indefinite-lived Intangible Assets [Roll Forward]
Balance, beginning			29,704	29,676	29,676
Removal of fully amortized assets			(702)
Foreign currency translation adjustments					28
Balance, ending	29,002		29,002		29,704
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance			(19,325)	(16,272)	(16,272)
Amortization expense			(1,798)		(3,025)
Removal of amortization of fully amortized assets			702
Foreign currency translation adjustments					(28)
Accumulated amortization, ending balance	(20,421)		(20,421)		(19,325)
Net balance	8,581		$ 8,581		$ 10,379
Weighted average life (in years)			10 years		10 years
Customer Lists and Contracts [Member]
Finite and Indefinite-lived Intangible Assets [Roll Forward]
Balance, beginning			$ 7,958	7,952	$ 7,952
Removal of fully amortized assets			(161)
Foreign currency translation adjustments					6
Balance, ending	7,797		7,797		7,958
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance			(3,085)	(2,326)	(2,326)
Amortization expense			(557)		(753)
Removal of amortization of fully amortized assets			161
Foreign currency translation adjustments					(6)
Accumulated amortization, ending balance	(3,481)		(3,481)		(3,085)
Net balance	4,316		$ 4,316		$ 4,873
Weighted average life (in years)			11 years		11 years
Other Identifiable Intangible Assets [Member]
Finite and Indefinite-lived Intangible Assets [Roll Forward]
Balance, beginning			$ 1,890	1,880	$ 1,880
Removal of fully amortized assets			(238)
Foreign currency translation adjustments					10
Balance, ending	1,652		1,652		1,890
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance			(860)	$ (715)	(715)
Amortization expense			(100)		(135)
Removal of amortization of fully amortized assets			238
Foreign currency translation adjustments					(10)
Accumulated amortization, ending balance	(722)		(722)		(860)
Net balance	930		$ 930		$ 1,030
Weighted average life (in years)			11 years		11 years
Goodwill [Member]
Intangible Assets [Line Items]
Asset Impairment Charges	$ 0				$ (1,159)

OTHER COMPREHENSIVE (LOSS) IN35

OTHER COMPREHENSIVE (LOSS) INCOME (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Balance as of December 31, 2014			$ (744)
Other comprehensive loss (income) before reclassifications			(351)
Amounts reclassified from accumulated other comprehensive income (loss)			0
Net current-period other comprehensive (loss) income	$ (18)	$ (425)	(351)	$ (828)
Balance as of September 30, 2015	(1,095)		(1,095)
Available-for-sale Securities [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Balance as of December 31, 2014			(17)
Other comprehensive loss (income) before reclassifications			24
Amounts reclassified from accumulated other comprehensive income (loss)			0
Net current-period other comprehensive (loss) income			24
Balance as of September 30, 2015	7		7
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Balance as of December 31, 2014			(727)
Other comprehensive loss (income) before reclassifications			(375)
Amounts reclassified from accumulated other comprehensive income (loss)			0
Net current-period other comprehensive (loss) income			(375)
Balance as of September 30, 2015	$ (1,102)		$ (1,102)

OTHER COMPREHENSIVE (LOSS) IN36

OTHER COMPREHENSIVE (LOSS) INCOME (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments, before tax	$ (19)		$ (375)
Foreign currency translation adjustments, tax benefit	0		0
Foreign currency translation adjustments, net of tax	(19)		(375)
Unrealized gains on available-for-sale investments, before tax	1		36
Unrealized gains on available-for-sale investments, tax benefit	0		(12)
Unrealized gains on available-for-sale investments, net of tax	1		24
Other comprehensive (loss) income, before tax	(18)		(339)
Other comprehensive (loss) income, tax benefit	0		(12)
Other comprehensive (loss) income, net of tax	$ (18)	$ (425)	$ (351)	$ (828)

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator:
Net income	$ 6,402	$ 5,550	$ 16,484	$ 16,241
Denominator:
Denominator for basic net income per share - weighted average common stock outstanding	42,152,000	41,714,000	42,041,000	41,496,000
Effect of dilutive securities: stock options and awards	404,000	667,000	313,000	631,000
Denominator for diluted net income per share - weighted average shares outstanding - diluted	42,556,000	42,381,000	42,354,000	42,127,000
Basic net income per share	$ 0.15	$ 0.13	$ 0.39	$ 0.39
Diluted net income per share	$ 0.15	$ 0.13	$ 0.39	$ 0.39
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive restricted stock awards, stock options	579,256	167,929	579,256	167,929

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details) $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Stock options, additional Disclosures [Abstract]
Total unrecognized compensation costs | $	$ 7.8
Unrecognized compensation costs, weighted average period of recognition (in years)	3 years 3 months 11 days
Stock Options [Member]
Stock options, outstanding [Roll Forward]
Options outstanding, beginning balance (in shares)	825
Granted (in shares)	962
Exercised (in shares)	(55)
Cancelled or expired (in shares)	(21)
Options outstanding, ending balance (in shares)	1,711
Stock options, additional Disclosures [Abstract]
Weighted-average price, beginning of period (in dollars per share) | $ / shares	$ 18.84
Weighted-average price, granted (in dollars per share) | $ / shares	15.94
Weighted average price, exercised (in dollars per share) | $ / shares	13.84
Weighted-average price, cancelled or expired (in dollars per share) | $ / shares	16.68
Weighted-average price, end of period (in dollars per share) | $ / shares	$ 17.40
Restricted Stock [Member]
Stock options, additional Disclosures [Abstract]
Total unrecognized compensation costs | $	$ 17.1
Unrecognized compensation costs, weighted average period of recognition (in years)	2 years 7 months 17 days
Equity instruments other than options, nonvested [Roll Forward]
Non-vested, beginning balance (in shares)	1,098
Granted (in shares)	276
Vested (in shares)	(322)
Cancelled or expired (in shares)	(152)
Non-vested, ending balance (in shares)	900
Equity instruments other than options, additional Disclosures [Abstract]
Non-vested, beginning balance (in dollars per share) | $ / shares	$ 19.63
Granted (in dollars per share) | $ / shares	15.95
Vested (in dollars per share) | $ / shares	19.17
Cancelled or expired (in dollars per share) | $ / shares	19.29
Non-vested, ending balance (in dollars per share) | $ / shares	$ 18.73
Restricted Stock Units (RSUs) [Member]
Stock options, additional Disclosures [Abstract]
Total unrecognized compensation costs | $	$ 3.9
Unrecognized compensation costs, weighted average period of recognition (in years)	2 years 1 month 13 days
Equity instruments other than options, nonvested [Roll Forward]
Non-vested, beginning balance (in shares)	658
Granted (in shares)	122
Vested (in shares)	(53)
Cancelled or expired (in shares)	(195)
Non-vested, ending balance (in shares)	532

STOCK-BASED COMPENSATION (Det39

STOCK-BASED COMPENSATION (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Cost of revenue
Share-based Compensation, allocation and classification in income statements [Abstract]
Stock-based compensation costs	$ 238	$ 233	$ 742	$ 743
Research and development
Share-based Compensation, allocation and classification in income statements [Abstract]
Stock-based compensation costs	725	726	1,705	1,862
Selling, general and administrative
Share-based Compensation, allocation and classification in income statements [Abstract]
Stock-based compensation costs	2,136	1,663	5,321	4,447
Selling, general and administrative
Share-based Compensation, allocation and classification in income statements [Abstract]
Stock-based compensation costs	$ 3,099	$ 2,622	$ 7,768	$ 7,052

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Accrued Employee Benefits, Current	$ 9,335	$ 9,960
Accrued Income And Other Taxes	846	870
Other Accrued Liabilities, Current	2,365	2,800
Accrued liabilities	13,005	$ 14,118
Accrued warranty costs [Roll Forward]
Accrued warranty costs as of December 31, 2014	488
Warranty adjustments/settlements	(465)
Accrual for warranty costs	436
Accrued warranty costs as of September 30, 2015	$ 459

INCOME TAXES (Details)

INCOME TAXES (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015
Effective tax rate, including amounts recorded for discrete events (in hundredths)	28.40%
Statutory rate (in hundredths)	35.00%
Maximum rate for cash taxes expected to be paid (in hundredths)	50.00%
Scenario, Forecast [Member]
Effective tax rate, including amounts recorded for discrete events (in hundredths)		30.00%

COMMITMENTS AND CONTINGENCIES C

COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
COMMITTMENTS AND CONTINGENCIES [Abstract]
Settlement of litigation	$ 0	$ 7,100	$ 0	$ (7,300)	$ 0

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2015
Subsequent Event [Line Items]
Settlement of litigation	$ 0	$ 7,100	$ 0	$ (7,300)	$ 0
Subsequent Event [Member]
Subsequent Event [Line Items]
Settlement of litigation						$ 2,000